EGFR mutations are significantly associated with visceral pleural invasion development in non-small-cell lung cancer patients
Authors Shi J, Yang Y, Zhao Y, Zhu J, Song X, Jiang G
Received 24 November 2018
Accepted for publication 31 January 2019
Published 1 March 2019 Volume 2019:11 Pages 1945—1957
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Antonella D'Anneo
Jinghan Shi, Yang Yang, Yanfeng Zhao, Junjie Zhu, Xiao Song, Gening Jiang
Department of Thoracic Surgery, Shanghai Pulmonary Hospital affiliated to Tongji University, Shanghai, China
Objectives: A retrospective study was performed to investigate the association between EGFR mutations and visceral pleural invasion (VPI), and evaluate the prognostic value of EGFR in resected non-small-cell lung cancer (NSCLC) patients with VPI.
Materials and methods: Clinicopathological characteristics and follow-up information were collected from 508 consecutive patients with surgically resected stage I–III NSCLC, and EGFR mutations were detected based on real-time PCR technology. Significant results (P<0.05) from univariate logistic regression analysis were involved as covariates to adjust confounding factors in the analysis of independent factors.
Results: VPI and EGFR mutations were detected in 229 (45.1%) and 243 (47.8%) cases in NSCLC, respectively. There was a significant association between EGFR mutations and VPI development. Both 19-del (adjusted OR =2.13, 95%CI =1.13–3.99, P=0.019) and L858R (adjusted OR =2.89, 95%CI =1.59–5.29, P=0.001) could significantly increase the risk of VPI development compared with EGFR wild-type. Higher frequency of L858R (adjusted OR =2.63, 95%CI =1.42–4.88, P=0.002) was detected in VPI patients compared with non-VPI patients. 19-del (adjusted HR =0.31, 95%CI =0.12–0.80, P=0.015) was an independent prognostic factor for a better disease-free survival (DFS) in non-VPI patients. No significant association was shown between EGFR mutations and DFS in VPI patients.
Conclusion: EGFR mutations were significantly associated with VPI development in NSCLC, but no significant association was observed between EGFR mutations and DFS in the patients with VPI. 19-del was a favorable prognostic factor for DFS in non-VPI patients.
Keywords: EGFR mutations, visceral pleural invasion, non-small-cell lung cancer, association study
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]